Every Form 4 that iRhythm Holdings, Inc. (IRTC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IRTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRTC filings page.
iRhythm Holdings, Inc. (IRTC) reported that its Chief Financial Officer, Daniel G. Wilson, sold 773 shares of common stock on September 2, 2026 at a price of $121.83 per share. According to a footnote, this sale was made to cover tax withholding and remittance obligations arising from the vesting of Restricted Stock Units.
After this transaction, he held 34,887 shares of common stock directly and an additional 100 shares indirectly through a family trust for which he serves as trustee. No transactions were reported as made under a Rule 10b5-1 trading plan.
iRhythm Holdings, Inc. reports that President and CEO Quentin S. Blackford had 48,534 shares of common stock credited to him upon the Compensation & Human Capital Management Committee’s determination that performance conditions for previously granted performance RSUs were met on August 7, 2026. On August 10, 2026, he sold 26,859 shares of common stock at $124.6514 per share to cover tax withholding and remittance obligations related to the vesting of those performance RSUs.
iRhythm Holdings, Inc. executive Patrick Michael Murphy, the company’s CBO and CLO, reported two equity transactions in common stock. On August 7, 2023 performance RSUs granted to him resulted in an acquisition of 13,589 shares upon determination that performance conditions were met. On August 10, 2026 he sold 7,093 shares of common stock at an average price of $124.6519 per share to cover tax withholding and remittance obligations related to the vesting of those performance RSUs. The Rule 10b5-1 trading plan box was not checked, indicating these transactions were not reported as occurring under a pre-arranged trading plan.
iRhythm Holdings, Inc. reported insider equity activity by Chief Commercial & Product Officer Chad Patterson. On August 7, 2026, he acquired 13,589 shares of common stock at no cost upon vesting of performance RSUs granted August 7, 2023. On August 10, 2026, he sold 7,093 shares of common stock at $124.6539 per share; the company states these shares were sold solely to cover tax withholding and remittance obligations related to the RSU vesting.
iRhythm Holdings, Inc. executive Sumi Shrishrimal, EVP and Chief Risk Officer, reported two common stock transactions. On August 7, 2026, she acquired 9,706 shares at no cost upon the Compensation & Human Capital Management Committee’s determination that performance conditions for previously granted performance RSUs were met. On August 10, 2026, 5,372 shares were sold at $124.6539 per share to cover tax withholding and remittance obligations related to that vesting.
iRhythm Holdings, Inc. reported insider equity activity by Chief Medical/Scientific Officer and EVP Advanced Technology Minang Turakhia. On August 7, 2026, he acquired 13,589 shares of common stock at $0.00 per share upon the Compensation & Human Capital Management Committee determining that performance conditions were met for previously granted performance RSUs from August 7, 2023. On August 10, 2026, he sold 7,093 shares of common stock at an average price of $124.6512 per share; these shares were sold to cover tax withholding and remittance obligations related to the vesting of the performance RSUs.
iRhythm Holdings, Inc. EVP Strategic Business Ops Mervin Smith reported selling 617 shares of common stock on August 3, 2026 at $122.1209 per share. The shares were sold to cover tax withholding and remittance obligations from vesting RSUs. After this sale, he directly holds 22,410 shares.
iRhythm Holdings, Inc. reported that EVP and Chief People Officer Julianne Rodda sold 2,112 shares of Common Stock on 2026-08-03 at an average price of $122.1209 per share. The shares were sold to cover tax withholding on RSU vesting, leaving her with 18,201 directly held shares.
iRhythm Holdings, Inc. reported that Chief Communications and Product Officer Chad Patterson sold 2,712 shares of common stock on 2026-08-03 at an average price of $122.1209 per share. The shares were sold to cover tax withholding and remittance obligations related to vesting Restricted Stock Units, and Patterson now directly holds 55,629 shares.
iRhythm Holdings, Inc. executive reports share sale tied to tax obligations. Chief Medical and Scientific Officer Minang Turakhia reported the sale of 1,423 shares of common stock on July 2, 2026 at an average price of $124.71 per share. A footnote explains these shares were sold to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units. After this transaction, Turakhia directly holds 53,620 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Sean Clinton Freeman, EVP of Strategy & Corporate Development, reported a sale of 918 shares of common stock at $124.71 per share. According to the footnote, these shares were sold solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units. After this tax-related transaction, he directly holds 13,641 shares, indicating a relatively small, routine reduction in his overall position.
iRhythm Holdings EVP and Chief Risk Officer Sumi Shrishrimal reported routine equity transactions. She acquired 133 shares of common stock at an average price of $96.815 per share through the company’s 2016 Employee Stock Purchase Plan for the period from December 1, 2025 through May 31, 2026, a transaction exempt from Section 16(b) under Rule 16b-3.
On June 2, 2026, she sold 1,716 shares of common stock at an average price of $108.1891 per share to cover tax withholding and remittance obligations related to vesting Restricted Stock Units. After these transactions, she directly owns 40,287 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported two recent transactions in the company’s common stock. He acquired 178 shares at $96.815 per share through the 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 to May 31, 2026, in a transaction exempt from Section 16(b) under Rule 16b-3. He also sold 729 shares at an average price of $108.1893 per share to cover tax withholding and remittance obligations arising from the vesting of Restricted Stock Units. After these transactions, he directly holds 16,155 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Minang Turakhia reported acquiring 137 shares of common stock, bringing his direct holdings to 55,043 shares. The shares were acquired through the company’s 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 through May 31, 2026 and are reported as an exempt award transaction under Rule 16b-3.
iRhythm Holdings, Inc. executive Chad Patterson reported acquiring 177 shares of common stock at $96.815 per share. The shares were purchased through the company’s 2016 Employee Stock Purchase Plan for the period from December 1, 2025 through May 31, 2026.
After this plan-related acquisition, Patterson directly holds 58,341 shares of iRhythm common stock. The filing notes that this transaction is exempt from Section 16(b) under Rule 16b-3 and is being reported on a voluntary basis.
iRhythm Holdings EVP Sean Clinton Freeman acquired additional company stock through a compensation plan. He received 273 shares of common stock on May 29, 2026 at $96.815 per share, increasing his direct holdings to 14,559 shares. The footnote explains this was a voluntary report of shares acquired under iRhythm’s 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 through May 31, 2026, and notes the transaction is exempt from Section 16(b) under Rule 16b-3, indicating it is a routine, plan-based acquisition rather than an open-market trade.
iRhythm Holdings, Inc. President and CEO Quentin S. Blackford reported an acquisition of 178 shares of common stock at $96.815 per share. The shares were acquired under the company’s 2016 Employee Stock Purchase Plan for the purchase period from December 1, 2025 through May 31, 2026, in a transaction exempt from Section 16(b) under Rule 16b-3. Following this Plan purchase, he holds 204,333 shares of common stock directly.
iRhythm Holdings director Cathleen Noel Bairey Merz received an equity award of 1,573 shares of Common Stock through restricted stock units. The grant was made at no cash cost to her and is a form of stock-based compensation rather than an open-market purchase.
Each RSU converts into one iRhythm share when it vests. The units vest on the earlier of one year after the grant date or the company’s next annual meeting. After this award, she directly holds 10,546 shares of iRhythm common stock.
Bodaken Bruce G. reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings director Bruce G. Bodaken received a stock-based award. He was granted 1,573 shares of common stock in the form of restricted stock units at no cash cost. Following this grant, he holds 14,211 shares directly. The RSUs vest on the earlier of one year after grant or the company’s next annual meeting.
iRhythm Holdings, Inc. director Karen Ling received an equity award in the form of restricted stock units. She acquired 1,573 shares of common stock at a grant price of $0.00 per share, increasing her direct holdings to 11,141 shares after the transaction.
The award consists of RSUs, each representing a contingent right to receive one share of iRhythm common stock. The RSUs vest on the earlier of one year after the grant date or the date of the company’s next annual meeting, tying the award to continued service on the board.
MCGINNIS KAREN K reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. director Karen K. McGinnis received an equity grant of 1,573 shares of common stock in the form of restricted stock units (RSUs). The award was granted at no cash cost per share and is part of her director compensation.
Each RSU represents a contingent right to receive one share of iRhythm common stock. The RSUs vest on the earlier of one year after the grant date or the company’s next annual meeting. After this grant, McGinnis directly holds 3,608 shares of common stock.
OBOYLE KEVIN C reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings director Kevin C. O’Boyle received an equity grant of 1,573 restricted stock units. The RSUs were awarded at no cash cost and each unit represents a right to one share of iRhythm common stock. The award vests on the earlier of one year after grant or the company’s next annual meeting. Following this grant, O’Boyle directly holds 3,608 shares.
TALWALKAR ABHIJIT Y reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. director Abhijit Y. Talwalkar received a grant of 1,573 shares in the form of restricted stock units. Each RSU represents a contingent right to receive one share of iRhythm common stock. The RSUs vest on the earlier of one year after grant or the company’s next annual meeting, bringing his direct holdings to 21,872 shares.
YOOR BRIAN B reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. director Brian B. Yoor reported receiving an equity award of 1,573 shares of common stock as a grant, with no cash paid per share. After this award, he holds 7,171 shares directly. The award consists of restricted stock units, each convertible into one share of common stock, vesting on the earlier of one year after grant or the company’s next annual meeting.
iRhythm Holdings, Inc. director Abhijit Y. Talwalkar reported option exercises and offsetting share sales under a pre-set trading plan. On May 11, 2026, he exercised 5,312 Employee Stock Options at $10.71 per share and acquired the same number of common shares.
That same day he sold an aggregate of 5,312 common shares in multiple open‑market transactions at prices ranging from about $115.61 to $120.53, resulting in no net change in his common stock holdings. After these transactions, he directly owned 20,299 common shares. All trades were executed pursuant to a Rule 10b5-1 trading plan established on May 12, 2025.
iRhythm Holdings, Inc. Chief Technology Officer Lawrence Brian Lee reported a small share disposition linked to equity compensation. On this Form 4, he sold 1,014 shares of common stock at $120.80 per share, and held 20,154 shares afterward.
According to the footnote, these shares were sold specifically to cover tax withholding and remittance obligations arising from the vesting of Restricted Stock Units (RSUs), indicating a routine, compensation-related transaction rather than a discretionary open-market sale for portfolio reasons.
Patten Jason H reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings director Jason H. Patten received a grant of 2,218 restricted stock units (RSUs) of Common Stock. Each RSU represents a contingent right to one share of iRhythm’s common stock. The RSUs vest 33.33% on March 12, 2027 and on each one-year anniversary thereafter, as long as he continues as a service provider. Following this award, Patten directly holds 4,436 shares/RSUs reported in this filing.
iRhythm Holdings EVP Mervin Smith reported an open-market sale of 2,585 shares of common stock at $114.30 per share. The transaction took place on March 16, 2026 and was executed under a pre-established Rule 10b5-1 trading plan adopted on November 19, 2025.
After this sale, Smith continues to hold 23,027 shares directly, indicating he retains a substantial equity position in the company despite the disposition.
iRhythm Holdings, Inc. reported that executive officer Minang Turakhia, its chief medical and scientific officer, executed open-market sales of a total of 4,027 shares of common stock on March 2, 2026 at prices around $128.45 per share. According to the footnote, these shares were sold specifically to cover tax withholding and remittance obligations arising from the vesting of restricted stock units. Following these transactions, Turakhia directly holds 54,906 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Sumi Shrishrimal, EVP and Chief Risk Officer, reported selling a total of 2,830 shares of common stock in three open-market transactions on March 2, 2026 at prices around $128.44 per share. According to the disclosure, these shares were sold to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs). Following these sales, Shrishrimal directly owned 41,870 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive vice president of strategic business operations Mervin Smith reported selling 1,352 shares of common stock on March 2, 2026 in open‑market transactions at prices around $128.44 per share. The filing states the shares were sold to cover tax withholding obligations from vesting restricted stock units, and Smith held 25,612 shares afterward.
iRhythm Holdings, Inc. executive Chad Patterson, the Chief Commercial & Product Officer, reported open-market sales totaling 4,444 shares of common stock on March 2, 2026, at prices around $128.44 per share.
According to the footnote, these shares were sold to cover tax withholding and remittance obligations tied to vesting Restricted Stock Units, and Patterson continues to hold 58,164 shares directly.
iRhythm Holdings, Inc. executive Patrick Michael Murphy, the company’s CBO and CLO, reported selling 4,357 shares of common stock on March 2, 2026. The shares were sold in several open-market transactions at prices around $128.44 per share to satisfy tax withholding and remittance obligations tied to the vesting of Restricted Stock Units. After these transactions, he continued to hold 63,203 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported two small sales of common stock related to equity compensation. On March 2, 2026, he sold 399 shares at $128.447 per share and 417 shares at $128.452 per share. A footnote states these sales were made to cover tax withholding and remittance obligations tied to vesting Restricted Stock Units, rather than discretionary selling. After these transactions, he directly held 16,706 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Financial Officer Daniel G. Wilson reported open-market sales of company common stock primarily for tax withholding. On March 2, 2026, he sold a total of 3,395 shares of common stock in several open-market transactions at prices around $128.44 per share to cover tax withholding and remittance obligations related to vesting Restricted Stock Units.
After these sales, Wilson directly owned 35,660 shares of iRhythm common stock and indirectly held 100 shares through The Wilson Living Trust dated July 9, 2015, of which he is the trustee.
iRhythm Holdings, Inc. President and CEO Quentin S. Blackford reported selling a total of 13,813 shares of common stock on March 2, 2026 at prices around $128.44 per share. According to the filing, these shares were sold to cover tax withholding obligations tied to vesting restricted stock units. After these transactions, he directly owned 204,155 shares of iRhythm common stock.
Wilson Daniel G. reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. Chief Financial Officer Daniel G. Wilson reported an equity award of 8,361 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock. Following this grant, his directly held common stock position is 39,055 shares.
According to the terms, 25% of the RSUs vest on March 1, 2027, with an additional 25% vesting on each one-year anniversary thereafter, so long as he continues as a service provider through each vesting date. The filing also notes an additional 100 shares of common stock held indirectly through The Wilson Living Trust dated July 9, 2015, for which Mr. Wilson serves as Trustee.
Turakhia Minang reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. reported that executive Minang Turakhia received an equity award in the form of Restricted Stock Units (RSUs) covering 10,034 shares of common stock at no cash cost on the grant date. Each RSU represents a right to receive one share if vesting conditions are met.
According to the vesting schedule, 25% of these RSUs vest on March 1, 2027, with the remaining RSUs vesting in equal portions on each one-year anniversary thereafter, as long as Turakhia continues as a service provider through each vesting date. Following this grant, Turakhia directly holds 58,933 shares of common stock.
iRhythm Holdings, Inc. reported that President and CEO Quentin S. Blackford acquired 31,842 shares of common stock through a grant of Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of common stock if vesting conditions are met. Following this award, he directly holds 217,968 shares. According to the grant terms, 25% of the RSUs vest on March 1, 2027 and on each one-year anniversary after that date, as long as he continues as a service provider.
Patterson Chad reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. reported that Chief Commercial & Product Officer Chad Patterson received an equity award in the form of restricted stock units. He was granted 10,870 RSUs, each representing a contingent right to receive one share of iRhythm common stock at no cash cost.
According to the vesting schedule, 25% of the RSUs vest on March 1, 2027, with additional 25% portions vesting on each one-year anniversary thereafter, as long as he continues as a service provider through each vesting date. Following this grant, his reported direct ownership increased to 62,608 shares of common stock.
Rosenbaum Marc Wade reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. reported that Chief Accounting Officer Marc Wade Rosenbaum received a grant of 2,508 Restricted Stock Units (RSUs) of common stock on February 25, 2026. Each RSU represents one share, with 25% vesting on March 1, 2027 and on each following one-year anniversary, subject to continued service. Following this award, his directly held common stock position is 17,522 shares.
Murphy Patrick Michael reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings executive Patrick Michael Murphy, the company’s CBO and CLO, received an equity award covering 7,024 shares of common stock in the form of Restricted Stock Units (RSUs). Each RSU represents a right to receive one share of common stock at vesting.
According to the filing, 25% of the RSUs vest on March 1, 2027, with an additional 25% vesting on each one-year anniversary thereafter, as long as he continues as a service provider through each vesting date. Following this grant, he holds 67,560 shares of common stock directly.
Smith Mervin reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings EVP Strategic Business Ops Mervin Smith received an equity award of 6,689 restricted stock units of common stock. These RSUs were granted on February 25, 2026 at no cash cost. 25% of the units vest on March 1, 2027 and on each one-year anniversary after that, so long as he continues as a service provider. Following this award, he directly holds 26,964 shares of common stock.
iRhythm Holdings, Inc. executive Sean Clinton Freeman, EVP of Strategy & Corporate Development, reported an equity award on Form 4. He acquired 7,525 shares of common stock through a grant of Restricted Stock Units at a stated price of $0.00 per unit, bringing his directly held total to 14,286 shares after the grant. The RSUs vest over four years, with 25% vesting on March 1, 2027 and additional 25% installments on each one-year anniversary, so long as he continues as a service provider through each vesting date.
Shrishrimal Sumi reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. executive Sumi Shrishrimal, EVP and Chief Risk Officer, received a grant of 5,518 shares of Common Stock in the form of Restricted Stock Units (RSUs) on February 25, 2026 at a stated price of $0.00 per share. Following this equity award, her directly held common stock position is reported as 44,700 shares. Each RSU represents a right to receive one share of common stock, with 25% of the RSUs scheduled to vest on March 1, 2027 and the remaining RSUs vesting in equal installments on each one-year anniversary thereafter, contingent on her continued service.
Lawrence Brian Lee reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings Chief Technology Officer Lawrence Brian Lee reported receiving an equity award tied to the company’s common stock. He was granted 6,689 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock for no cash payment.
According to the award terms, 25% of the RSUs vest on March 1, 2027 and on each one-year anniversary thereafter, as long as he continues as a service provider through each vesting date. After this grant, Lee directly holds 21,168 shares of common stock, reflecting his increased equity-based stake in the company.
iRhythm Holdings Chief Financial Officer Daniel G. Wilson reported RSU vesting and related share sales. On February 24, 2026, he acquired 9,412 shares of common stock at no cost upon the Compensation & Human Capital Management Committee determining performance RSU conditions were met. On February 25, 2026, he sold 5,188 shares at an average price of $135.4189 to cover tax withholding and remittance obligations from the RSU vesting. After these transactions, he directly held 30,694 shares and indirectly held 100 shares through The Wilson Living Trust, where he serves as trustee.
iRhythm Holdings executive Minang Turakhia, Chief Medical/Scientific Officer and EVP Advanced Technology, reported a mix of equity award and related share sale. On February 24, 2026, he acquired 15,060 shares of common stock at $0.00 per share through the vesting of performance RSUs granted on February 27, 2023, after the compensation committee determined the performance conditions were met. On February 25, 2026, he sold 7,804 shares at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to this vesting. Following these transactions, he directly held 48,899 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive vice president Mervin Smith reported performance-based equity vesting and related tax sales of company stock. He acquired 9,210 shares of common stock on February 24, 2026 at $0.00 per share from performance RSUs after a board committee determined the performance conditions were met.
On February 25, 2026, he sold 4,041 shares of common stock at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to the RSU vesting. After these transactions, he directly owned 20,275 shares of iRhythm common stock.
iRhythm Holdings EVP and Chief Risk Officer Sumi Shrishrimal reported equity compensation activity and a related tax sale. On February 24, 2026, she acquired 11,294 shares of common stock at $0.00 per share from performance RSUs granted on February 27, 2023, after the board committee determined performance conditions were met. This increased her direct holdings to 45,399 shares. On February 25, 2026, she sold 6,217 shares of common stock at an average price of $135.4189 per share, leaving 39,182 shares held directly. A footnote states these shares were sold to cover tax withholding and remittance obligations tied to the vesting of the performance RSUs.